Not Signed In - Somaxon Pharmaceuticals' SILENOR(TM) Demonstrates Positive Results In A Phase 3 Transient Insomnia Clinical Trial
Tue, 24 Oct 2006 07:00 AM EST
... Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) today announced positive results from the company's Phase 3 clinical trial evaluating SILENOR(TM) (doxepin HCl) in adults with transient insomnia. [click link for full article] ...
Related Topics
- Clinical Trials
- Insomnia
- Stroke, Transient
- Pharmacology
- Trastuzumab
- Psychopharmacology
- Tarceva
- Food Recommendations: South Beach Diet - Phase 1
- Food Recommendations: South Beach Diet - Phase 2
- Clinical Growth Charts
- Tb
- Bevacizumab Injection
- Crohn's Disease
- Pancreatic Cancer
- Transient tachypnea - newborn
- Transient familial hyperbilirubinemia
- Transient tic disorder
- Brain injury that results in physical, emotional, or intellectual changes or deficits
- Primary Insomnia
- Patient Issues
email this page
print this page
bookmark this page
feedback on this page
